Newsletter Derm Brief

Highlight

Neoadjuvant immunotherapy combo produces high response rate in melanoma

Highlight

Dupilumab provides option for severe AD in younger children

Highlight

5-Year Analysis of Adjuvant Dabrafenib/Trametinib in Stage III Melanoma

Highlight

Melanoma experts say ‘no’ to routine gene profile testing

Highlight

Introducing: LiVDerm

Highlight

Dupilumab pre-filled pen approved by FDA

Highlight

Galderma Announces FDA Approval for Restylane Kysse

Highlight

AAD and NPF Issue Joint Guidelines on Psoriasis

Highlight

AAD Updates Guidance on Biologic Therapy Use During COVID-19

Highlight

Study Sheds Light on Relationship Between cSCC and Indoor Tanning

Highlight

Xolair Proves Effective in Treating AD Symptoms Within Children

Highlight

Study Finds Majority of Acne Patients Open to Antibiotic-free Treatment

Highlight

Study Examines Natural Course of Alopecia Areata in Young Children

Highlight

Research Identifies Epigenetic Regulator That Controls Skin Cell Turnover

Highlight

'Virtual biopsy' device developed to detect skin tumors

Highlight

Immunotherapy Combo Fails to Slow Progression of Melanoma

Highlight

New Research Identifies Optimal Uses for 18 Popular HA Fillers

Highlight

Mortality Marker Pinpointed for Dermatomyositis

Highlight

New Home Light Therapy System Proves Effective in Psoriasis Treatment

Highlight

New Study Demonstrates Loss of Volume in Upper Lip Causes Aging

TEST YOUR KNOWLEDGE